This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Heidelberg Immunotherapeutics Gmbh, Rheinische Friedrich-Wilhelms-Universitat Bonn, Universität Duisberg Essen. Active years: 2014-2017.
Company Filing History:
1 out of 1 
1 out of 31 
1 out of 1 Years Active: 2014-2017
Title: Adalbert Krawczyk: Innovator in Anti-HSV Antibody Research
Introduction
Adalbert Krawczyk is a notable inventor based in Muelheim, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of anti-HSV antibodies. His work has implications for the treatment of HSV-associated diseases, showcasing his commitment to advancing medical science.
Latest Patents
Krawczyk holds 2 patents related to anti-HSV antibodies. His inventions include a pharmaceutical composition that comprises an effective amount of the antibody, an expression vector containing a nucleotide sequence that encodes the antibody, and a hybridoma cell capable of producing the antibody. These patents emphasize the use of the antibody as a drug for the prophylactic or therapeutic treatment of HSV-associated diseases.
Career Highlights
Throughout his career, Krawczyk has worked with prominent organizations such as Heidelberg Immunotherapeutics GmbH and Universität Duisburg Essen. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Krawczyk has collaborated with notable colleagues, including Michael Roggendorf and Anna-Maria Eis-Hübinger. These partnerships have enriched his research and expanded the impact of his innovations in the medical field.
Conclusion
Adalbert Krawczyk's work in developing anti-HSV antibodies represents a significant advancement in the fight against viral diseases. His patents and collaborations highlight his dedication to improving healthcare through innovative solutions.